{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-006273","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2026-09-29T11:03:38+00:00","discovered_at":"2026-09-29T11:05:00.177267+00:00","generated_at":"2026-10-12T13:41:29.076629+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BeyondSpring wins FDA Fast Track for Plinabulin in post-ICI NSCLC; sells China unit to fund DUBLIN-4","bullets":["FDA granted Fast Track designation to Plinabulin plus docetaxel for 2L/3L advanced non-squamous NSCLC without actionable genomic alterations, post-ICI and platinum chemo.","DUBLIN-4 Phase 3: ~442 patients randomized 1:1, overall survival primary endpoint with PFS and ORR secondary; prespecified interim analysis at 221 PFS events.","BeyondSpring will sell BeyondSpring Ltd, which indirectly holds its majority stake in Dalian Wanchunbulin (Bulin), to Biolin Investment for no cash; Biolin funds the China portion of DUBLIN-4.","If Bulin misses Target Enrollment within 3 years after closing and the shortfall is 90% or more, Biolin must return 100% of the Equity Interests to BeyondSpring.","ATM program with Citizens JMP Securities covers up to 9,200,000 ordinary shares; agent commission up to 3.0% of gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-006273","json":"https://secwatch.observer/filing/0001171843-26-006273.json","markdown":"https://secwatch.observer/filing/0001171843-26-006273.md","text":"https://secwatch.observer/filing/0001171843-26-006273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326006273/0001171843-26-006273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326006273/f8k_092826.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:41:29.076629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}